GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » Other Long Term Assets

Incyte (BSP:I1NC34) Other Long Term Assets : R$6,105 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Incyte Other Long Term Assets?

Incyte's other long-term assets for the quarter that ended in Sep. 2024 was R$6,105 Mil.

Incyte's quarterly other long-term assets increased from Mar. 2024 (R$4,880 Mil) to Jun. 2024 (R$5,431 Mil) and increased from Jun. 2024 (R$5,431 Mil) to Sep. 2024 (R$6,105 Mil).

Incyte's annual other long-term assets declined from Dec. 2021 (R$3,029 Mil) to Dec. 2022 (R$2,959 Mil) but then increased from Dec. 2022 (R$2,959 Mil) to Dec. 2023 (R$4,375 Mil).

Incyte Other Long Term Assets Historical Data

The historical data trend for Incyte's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Other Long Term Assets Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 228.04 322.90 3,028.74 2,958.61 4,374.56

Incyte Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,897.34 4,374.56 4,879.63 5,431.22 6,104.87

Incyte Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Incyte Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » Other Long Term Assets
Comparable Companies
SMMT BMRN NEUP INSM SRPT TECH RPRX MRNA UTHR PCVX VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
INCY:USA INCY:Mexico 1INCY:Italy 0J9P:UK ICY:Germany
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Website
https://www.incyte.com
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines